APA (7th ed.) Citation

OE, R., JE, R., A, G., G, S. E. R., O, A., P, M., . . . SN, K. (2021). Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(2), 485. https://doi.org/10.1158/1078-0432.CCR-20-2669

Chicago Style (17th ed.) Citation

OE, Rahma, Reuss JE, Giobbie-Hurder A, Shoja E Razavi G, Abu-Shawer O, Mehra P, Gupta S, Simon R, and Khleif SN. "Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 27, no. 2 (2021): 485. https://doi.org/10.1158/1078-0432.CCR-20-2669.

MLA (9th ed.) Citation

OE, Rahma, et al. "Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 27, no. 2, 2021, p. 485, https://doi.org/10.1158/1078-0432.CCR-20-2669.